13F reference period
Q3 2026
Security Snapshot
PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (PVCT) Institutional Ownership
CUSIP: 74373P108
13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026
Institutions Reporting
3
Shares (Excl. Options)
129.81K
Full value: 129,811 · shares · 30 Sep 2026Price
$0.06
The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Symbol
- PVCT on OTC
- All holders as of 30 Sep 2026
- Q3 2026
- Total 13F shares
- 129,811
- Total 13F value
- $7,402
- Share change
- 0
- Number of holders
- 3
- Shares outstanding
- 451,690,568
- SEC-reported price per share
- $0.06
Latest holder snapshot
3 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- PVCT - PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share is tracked under CUSIP 74373P108.
- 3 institutions reported positions in Q3 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 3 to 3 between Q2 2026 and Q3 2026.
- SEC-reported value moved from to
$8.97K
Full value: $8,969 · USD · 30 Jun 2026.$7.4K
Full value: $7,402 · USD · 30 Sep 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 3 institutions filings for Q3 2026.
Security key
74373P108
13F reference period
Q3 2026
13F holders
3
13D/G owners
2
CIK / CUSIP context first
Open Q3 2026 holders
PVCT full holder history
PROVECTUS BIOPHARMACEUTICALS, INC. SEC filings
PROVECTUS BIOPHARMACEUTICALS, INC. company facts
PROVECTUS BIOPHARMACEUTICALS, INC. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74373P108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
PVCT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Pershing Edward | 12% | +9.5% | $3,628,936 | +$220,428 | 52,441,275 | +6.5% | Pershing Edward | 30 Jun 2026 |
| Rodrigues Dominic | 5.7% | $1,513,233 | 25,220,549 | Dominic Rodrigues | 02 Dec 2025 |
As of 30 Sep 2026,
3
institutional investors reported holding
shares of
PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (PVCT).
This represents
0.03%
of the company’s total
outstanding shares.
129.81K
Full value: 129,811 · shares · 30 Sep 2026451.69M
Full value: 451,690,568 · shares · Stored outstanding share countQuarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 129,811 | $7,402 | $0.06 | 3 | |
| 2026 Q2 | 129,811 | $8,969 | -$3,695 | $0.07 | 3 |
| 2026 Q1 | 202,411 | $10,375 | +$999 | $0.05 | 5 |
| 2025 Q4 | 182,791 | $10,228 | -$4,149 | $0.06 | 4 |
| 2025 Q3 | 229,411 | $20,417 | +$53 | $0.09 | 6 |
| 2025 Q2 | 228,811 | $17,074 | $0.07 | 6 | |
| 2025 Q1 | 228,811 | $22,881 | $0.10 | 6 | |
| 2024 Q4 | 176,811 | $21,225 | -$5,000 | $0.12 | 5 |
| 2024 Q3 | 226,811 | $22,320 | -$196 | $0.10 | 6 |
| 2024 Q2 | 228,811 | $28,570 | $0.13 | 6 | |
| 2024 Q1 | 178,811 | $32,710 | $0.18 | 5 | |
| 2023 Q4 | 228,811 | $21,859 | $0.10 | 6 | |
| 2023 Q3 | 218,620 | $18,155 | -$865 | $0.08 | 5 |
| 2023 Q2 | 226,270 | $25,970 | $0.11 | 6 | |
| 2023 Q1 | 226,270 | $36,784 | $0.16 | 6 | |
| 2022 Q4 | 218,620 | $23,232 | -$2,000 | $0.11 | 5 |
| 2022 Q3 | 256,650 | $12,000 | -$2,000 | $0.05 | 6 |
| 2022 Q2 | 292,309 | $17,000 | -$158,062 | $0.06 | 6 |
| 2022 Q1 | 2,616,923 | $176,000 | -$1,099 | $0.06 | 6 |
| 2021 Q4 | 2,639,300 | $146,000 | +$130,000 | $0.06 | 6 |
| 2021 Q3 | 236,520 | $15,000 | +$8 | $0.06 | 6 |
| 2021 Q2 | 236,857 | $16,000 | $0.07 | 6 | |
| 2021 Q1 | 236,857 | $16,000 | +$1,252 | $0.07 | 6 |
| 2020 Q4 | 218,457 | $13,000 | +$1,000 | $0.06 | 5 |
| 2020 Q3 | 196,000 | $16,000 | $0 | $0.08 | 4 |